JY231 clinical trials
How each study uses JY231 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the JY231 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2025 (9)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 9
He Huang (3) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (3) · Tongji Hospital (2) · Shenzhen Genocury Biotech Co., Ltd. (2) · LiangZou (1) · Affiliated Hospital of Guangdong Medical University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test JY231.
- Dec 2026CAR-T Therapy for Refractory Autoimmune DiseasesNot applicable · LiangZou
- Dec 2026JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaNot applicable · Tongji Hospital
- Dec 2026JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune DisordersNot applicable · Tongji Hospital
Studies
Open first, then newest update. How each study uses JY231 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNot applicableLiangZouNCT07059169Written as JY231 (JY231 injection)
- JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingEarly Phase 1920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaNCT06514768Written as JY231
- JY231(JY231) Injection for the Treatment of R/R B-cell MalignanciesRecruitingNot applicable920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaNCT07065279Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableTongji HospitalNCT06689917Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableAffiliated Hospital of Guangdong Medical UniversityNCT06940960Written as JY231 Injection
- JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune DisordersRecruitingNot applicableTongji HospitalNCT06797024Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableShenzhen Genocury Biotech Co., Ltd.NCT06890065Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell LeukemiaNot yet recruitingNot applicableHe HuangNCT06902025Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)Not yet recruitingNot applicableHe HuangNCT06887985Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell LymphomaNot yet recruitingNot applicableHe HuangNCT06879470Written as JY231 Injection
- JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaRecruitingNot applicableShenzhen Genocury Biotech Co., Ltd.NCT06678282Written as JY231 Injection
- JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)RecruitingPhase 1/2920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaNCT06675422Written as JY231 injection